Jacobson Pharma Corporation

Jacobson Pharma Corporation Liabilities

The The Liabilities of Jacobson Pharma Corporation (2633.HK) as of Nov 13, 2026 is 1.22 B HKD. In the previous year, The Liabilities was 1.17 B HKD — a change of 4.79% (higher).

Liabilities

1.22 BHKD

YoY

4.79%

Last updated:

In 2026, Jacobson Pharma Corporation's total liabilities amounted to 1.22 B HKD, a 4.79% difference from the 1.17 B HKD total liabilities in the previous year.

The Jacobson Pharma Corporation Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
1.57 B HKD
Jan 1, 2020
1.97 B HKD
Jan 1, 2021
2.01 B HKD
Jan 1, 2022
1.80 B HKD
Jan 1, 2023
2.12 B HKD
Jan 1, 2024
1.09 B HKD
Jan 1, 2025
1.17 B HKD
Jan 1, 2026
1.22 B HKD
The Jacobson Pharma Corporation Liabilities history
YEARLiabilitiesYoY
1.22 BHKD+4.79%
1.17 BHKD+7.08%
1.09 BHKD-48.66%
2.12 BHKD+18.16%
1.80 BHKD-10.44%
2.01 BHKD+1.67%
1.97 BHKD+25.46%
1.57 BHKD-1.85%
1.60 BHKD+33.85%
1.20 BHKD+38.32%
865.91 MHKD+23.95%
698.58 MHKD+29.41%
539.82 MHKD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jacobson Pharma Corporation Stock analysis

What does Jacobson Pharma Corporation do? Jacobson Pharma Corp. Ltd. generates revenue through its Generic Drugs segment, which develops, manufactures, and distributes off-patent medicines for public and private sectors. The Branded Healthcare segment offers branded medicines, proprietary Chinese medicines, and health and wellness products. Both segments operate primarily in Hong Kong, serving healthcare providers and consumers seeking cost-effective pharmaceutical solutions. The company employs 1,789 full-time employees to support its operations across these segments. The Generic Drugs segment focuses on off-patent medicines for various therapeutic uses, targeting hospitals, clinics, and pharmacies in both public and private healthcare systems. The Branded Healthcare segment caters to consumers and healthcare providers through branded pharmaceuticals and wellness products, emphasizing proprietary Chinese medicines as a key offering. Revenue streams are derived from direct sales of these products within Hong Kong's healthcare market. Jacobson Pharma's business model relies on the dual revenue streams from generic and branded pharmaceuticals. The company's product portfolio includes off-patent medicines under the Generic Drugs segment and branded medicines under the Branded Healthcare segment, both contributing to its overall sales. The firm's operations are structured around these two segments, with all activities concentrated in Hong Kong. Jacobson Pharma Corporation is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Jacobson Pharma Corporation's Liabilities

Jacobson Pharma Corporation's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Jacobson Pharma Corporation's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Jacobson Pharma Corporation's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Jacobson Pharma Corporation's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Jacobson Pharma Corporation’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Jacobson Pharma Corporation stock

The Liabilities of Jacobson Pharma Corporation is 1.22 B HKD in 2026.

The Liabilities of Jacobson Pharma Corporation changed from 1.17 B HKD to 1.22 B HKD, representing a 4.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Jacobson Pharma Corporation since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's HKD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Jacobson Pharma Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Jacobson Pharma Corporation

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Jacobson Pharma Corporation